Propanc Biopharma PPCB 深 滬
已收盤 02-06 16:00:00 美东时间
0.1898
-0.012
-5.99%
華盛通- 最 高0.20
- 今 開0.19
- 成交量 209.16万股
- 最 低 0.1629
- 昨 收 0.2019
- 總市值 286.43万
- 52周最高 0.8101
- 市盈率 靜 --
- 換手率 13.86%
- 52周最低 0.1555
- 委 比 -71.43%
- 總股本 1509.11万
- 歷史最高 0.8101
- 量 比 0.23
- 振 幅 18.38%
- 歷史最低 0.1555
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Propanc Biopharma Highlights Potential Of Proenzyme Therapy, PRP, To Compete With Existing Approved Therapies For Solid Tumors
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlighted
02-05 21:46
Propanc Biopharma Files Fourth Provisional Patent; Expands IP Portfolio To Advance PRP Proenzyme Therapy For Metastatic Cancer
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the
01-27 21:49
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
Propanc Biopharma has filed its fourth provisional patent application in two months with IP Australia, focusing on innovative formulations of pancreatic proenzymes to address stability, storage, and transport challenges. This rapid IP expansion aims to double the company's patent portfolio to over 200 worldwide, reinforcing its leadership in preventing metastatic cancer. The advancements in proenzyme technology, particularly for PRP, a novel intr...
01-27 13:45
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
Propanc Biopharma's PRP, a pancreatic proenzyme formulation, targets cancer stem cells and aims to inhibit metastasis and enhance chemosensitivity in pancreatic cancer. Preclinical studies show promising results, including reduced tumor growth and improved tumor microenvironment. PRP has received Orphan Drug Designation from the FDA. Propanc plans to initiate Phase I/II clinical trials in 2026. The pancreatic cancer market is projected to grow at...
01-15 13:45
Propanc Biopharma Provides Shareholder Update
Propanc Biopharma's CEO highlights 2025 progress and outlines 2026 plans, focusing on advancing PRP, a pancreatic proenzymes-based therapy for advanced cancers, into a Phase 1b clinical trial at Peter MacCallum Cancer Centre. The company also strengthens its scientific platform with research collaborations, expanding into fibrosis and advancing Rec-PRP, a synthetic version of PRP. With strong R&D investment and a robust IP portfolio, Propanc aims...
01-13 13:45
Propanc Announces Publication Of Key Findings In Peer Reviewed Journal, Scientific Reports, Regarding Impact Of Proenzymes On Pancreatic Ductal Adenocarcinoma Fibroblasts
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced that the Company
2025-12-22 20:12
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
2025-12-06 05:05
Propanc Biopharma Submits Request For Foreign Filing License From Spain For Two Provisional Patents To Treat Resistant Cancer, Fibrosis
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced that it has submitted a request for a
2025-12-01 21:48
Propanc Biopharma, Inc. GAAP EPS of $0.39
Propanc Biopharma, Inc. press release (PPCB): Q1 GAAP EPS of $0.39. More on Propanc Biopharma, Inc. Propanc Biopharma secures up to $100 million private placement Propanc Biopharma announces up to $10...
2025-11-18 00:27
Propanc Biopharma Secures $1M Through Stock Sale
Propanc Biopharma ( ($PPCB) ) has provided an announcement. On November 4, 2025...
2025-11-11 06:55
